Clearside Biomedical - Case Summary

Business Description Headquartered in Alpharetta, GA, Clearside Biomedical, Inc. ("Clearside" or the "Debtor") is a clinical-stage biopharmaceutical company ...

Business Description

Headquartered in Alpharetta, GA, Clearside Biomedical, Inc. ("Clearside" or the "Debtor") is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for serious eye diseases.

The Company's core technology is its proprietary suprachoroidal space (SCS®) injection platform, which utilizes a specialized medical device, the SCS Microinjector®, to enable targeted, non-surgical drug delivery to the back of the eye.
This approach places medication between the sclera and choroid, enhancing efficacy while reducing systemic side effects compared to traditional delivery methods.

Clearside operates a business model that integrates internal product development with strategic partnerships. While advancing its own pipeline of clinical and preclinical candidates, the Company collaborates with leading pharmaceutical firms—including Bausch + Lomb, Arctic Vision, REGENXBIO (with AbbVie), Aura Biosciences, and BioCryst Pharmaceuticals—to expand the application of its SCS Microinjector across indications such as inflammation, neovascular disorders, and eye cancers.

The Debtor has one wholly owned subsidiary, Clearside Royalty LLC ("Clearside Royalty"), which is not a debtor in this Chapter 11 proceeding.

For the nine months ended September 30, 2025, Clearside reported revenue of $3.0 million, consisting entirely of non-cash revenue from license and collaboration agreements, with no product sales revenue recognized due to the assignment of rights to Clearside Royalty.

The Company reported a net loss of $18.7 million for the same period, an improvement from a $27.0 million net loss in the prior year, attributed to reduced clinical trial investments and workforce reductions.
As of September 30, 2025, the Company carried an accumulated deficit of $374.0 million.

Clearside Biomedical, Inc. filed for Chapter 11 protection with approximately $3.014 million in cash on hand as of the Petition Date.

Corporate History

Clearside was founded in 2011 and incorporated in Delaware. From 2011 to 2016, the Company operated privately, funded by convertible preferred equity and debt, while securing intellectual property rights and developing its suprachoroidal microinjector technology.

Public Listing and Development

In June 2016, Clearside completed its IPO, raising approximately $51 million to support its pipeline. Its common stock trades on the Nasdaq Global Market under the ticker symbol "CLSD."
Since going public, Clearside has focused on advancing clinical programs and securing strategic partnerships to commercialize treatments for severe eye diseases.

Royalty Monetization and Financing

In August 2022, Clearside executed a royalty sale transaction with entities managed by HealthCare Royalty Management, LLC (HCR) to monetize its assets.

Creation of Clearside Royalty: Clearside contributed key intellectual property and license agreements (including XIPERE and SCS Microinjector technology) to its non-debtor subsidiary, Clearside Royalty.
Royalty Sale: Clearside Royalty sold rights to receive royalties and milestones to HCR for up to $65 million. Clearside pledged 100% of its equity in Clearside Royalty as security for these obligations.
2025 Amendment: On September 4, 2025, the parties amended the agreements. HCR provided an additional $3 million in consideration, which Clearside Royalty used to acquire additional assets from Clearside, including manufacturing documentation and regulatory filings necessary for the SCS Microinjector.

Strategic Restructuring

Facing liquidity constraints, Clearside implemented significant cost-saving measures in mid-2025. On July 18, 2025, the Company executed a workforce reduction plan, transitioning all full-time employees and executive officers to hourly consulting roles to conserve cash while exploring strategic alternatives.

Operations Overview

Clearside operates out of a single leased facility in Alpharetta, GA, which serves as its corporate headquarters and research hub. The Company relies on third-party manufacturers and strategic partners to advance its product portfolio.

Product Portfolio

XIPERE® (Approved): Clearside’s first FDA-approved product, used for treating macular edema associated with uveitis.
- Commercialized in North America by Bausch + Lomb and in Asia-Pacific markets by Arctic Vision (branded as ARCATUS®).
CLS-AX (Clinical Stage): An injectable suspension of axitinib developed for wet AMD. Delivered via the SCS Microinjector, it is designed to reduce dosing frequency to every three to six months.
- Following positive Phase 2 results, Clearside has aligned with the FDA on the design for Phase 3 pivotal trials.
Preclinical Programs: A portfolio of small molecule candidates targeting retinal diseases, including geographic atrophy and diabetic macular edema.

Intellectual Property and Manufacturing

Clearside maintains a robust IP portfolio essential to its platform, comprising 35 issued U.S. patents and 112 foreign patents. The portfolio includes foundational microneedle delivery technology in-licensed from Emory University and Georgia Tech Research Corporation.

Manufacturing: Clearside outsources production, holding a key supply agreement with Gerresheimer Regensburg GmbH for the manufacture of the SCS Microinjector.
- Rights to the Gerresheimer agreement were recently transferred to Clearside Royalty to ensure continued production capabilities for the non-debtor subsidiary.

Workforce

As of the Petition Date, Clearside has no full-time employees. Previously employing 31 individuals, the Company transitioned its entire workforce to hourly consulting roles effective July 18, 2025.

Consultants, including the CEO, CFO, and CMO, continue to provide essential services related to regulatory compliance, supply chain management, and partner support to maintain business continuity during the wind-down process.

Prepetition Obligations

As of the Petition Date, the Debtor has no funded debt obligations, including secured debt, and no outstanding trade debt. The company’s cash on hand is unencumbered and may be used to fund the administration of its chapter 11 case and ongoing operations without the need for secured creditor consent or third-party financing.

Events Leading to Bankruptcy

Financial Distress and Liquidity Crisis

As a clinical-stage biopharmaceutical company, Clearside Biomedical, Inc. has historically relied on external capital—including equity offerings and licensing agreements—to fund its operations, leading to sustained financial distress and substantial operating losses without generating meaningful product revenue.
The Company's deteriorating liquidity position created significant doubt about its ability to continue as a going concern. As of September 30, 2025, Clearside reported:
- Approximately $6.8 million in cash and cash equivalents.
- Total liabilities of $65.6 million, including $61.2 million related to a sale of future royalties.
- An accumulated deficit of $374.0 million.
- A cash runway projected to last only into the fourth quarter of 2025.

Nasdaq Listing Non-Compliance

Clearside faced delisting pressure after receiving two notices from Nasdaq for non-compliance with listing rules. The first, on February 7, 2025, was for failing to meet the minimum bid price requirement. The second, on August 28, 2025, concerned the minimum market value of its listed securities.
In an attempt to regain compliance with the minimum bid price rule, the Board authorized a reverse stock split, which was executed on September 12, 2025.

Strategic Review and Advisor Engagement

In response to its financial constraints, Clearside’s Board and its Strategic Committee initiated a comprehensive review of strategic alternatives in late 2024 and early 2025 to preserve and maximize stakeholder value.
To support this process, the Company retained a team of professional advisors in the spring of 2025, including:
- Berkeley Research Group, LLC (“BRG”) as its financial advisor.
- Piper Sandler & Co. (“Piper”) as its investment banker to explore transactions such as asset sales, mergers, and licensing arrangements.
In parallel, Clearside implemented significant cost-cutting measures, including a company-wide workforce reduction and a pause on internal research and development activities to preserve cash.

Exhaustion of Strategic Alternatives

With its advisors, Clearside launched a comprehensive marketing process to identify a merger or sale partner, focusing on likely strategic buyers within the specialized pharmaceutical and life sciences sector. The Company also explored merger opportunities with parties interested in leveraging its public company status.
The prepetition marketing efforts included:
- Contacting 41 prospective buyers.
- Holding preliminary discussions with nine parties.
- Executing non-disclosure agreements with 11 parties, who were granted access to a virtual data room.
Simultaneously, the Company engaged Citizens Bank N.A. to pursue a private offering of its securities to raise additional capital. Despite meetings with 71 potential investors, Clearside was unable to secure sufficient commitments.

Pivot to a Section 363 Sale Process

While the broad marketing process failed to produce a viable out-of-court solution, it resulted in a non-binding term sheet from a potential stalking horse bidder for the purchase of certain assets.
After extensive negotiations and with liquidity dwindling, the Board concluded that a Chapter 11 filing to execute a court-supervised sale under section 363 of the Bankruptcy Code was the only viable path to maximize value for all stakeholders.
The Debtor plans to use its sufficient unencumbered cash on hand to fund the administration of the Chapter 11 case and will seek to finalize the stalking horse agreement to establish a baseline bid for its assets, which will be marketed postpetition to solicit higher or better offers.